Highest-materiality recent filing
Jesse Geiger to resign as President effective May 31, 2026; not due to disagreement.
Board approved $1.0B increase to stock repurchase program; timing based on market conditions.
Medpace shareholders approve board declassification; annual director elections start 2025
Stockholders approved amendment to phase out classified board; directors elected annually beginning at 2025 annual meeting.
Medpace Q2 revenue $469.4M (+27% YoY), EPS $2.35 (+62%); raises FY 2023 guidance
Revenue $469.4M (+27.4% YoY), net income $75.6M (+62.5%), diluted EPS $2.35.
Medpace Q3 earnings released; Board authorizes $500M share buyback
Board authorized share repurchases of up to $500M of common stock on Oct 21, 2022.
Medpace reports Q2 2022 revenue $351.2M (+26.2% YoY), diluted EPS $1.46 vs $1.06
Revenue $351.2M, up 26.2% YoY; constant currency organic growth 27.7%.
Medpace boosts buyback by $60M; retired 1.6M shares (~5% of float) in past month
Board approved $60M increase to existing stock repurchase program on May 25, 2022.
Medpace Q1 revenue up 27.3% to $330.9M; EPS $1.69 vs $1.14 YoY
Revenue $330.9M, +27.3% YoY; constant-currency organic growth +28.1%.
Medpace increases credit facility to $250M and expands share buyback by $200M
Amendment No. 4 raises line of credit from $50M to $250M with PNC Bank, maturing March 31, 2023.
Q4 2021 GAAP net income $50.0M ($1.32 EPS) vs $50.9M ($1.35 EPS) prior year; net income margin 16.2%.
Medpace Q3 revenue $295.6M (+28.3%), EPS $1.29; net new awards $408M
Revenue $295.6M, up 28.3% YoY; net income $48.6M ($1.29 diluted EPS) vs $41.5M ($1.09) prior year.
Medpace Q2 2021 revenue up 35.8% to $278.3M; net income $39.9M ($1.06 EPS)
Net new business awards of $387.6M (+52.5% YoY) produced a 1.39x book-to-bill ratio.
Effective June 1, 2026, Medpace Holdings, Inc. (the “ Company ”) appointed Brad W. Hansman, age 43, to the position of Executive Vice President, Operations.
On June 28, 2024, Ashley M. Keating, a member of the Board of Directors (the “Board”) of Medpace Holdings, Inc. (the “Company”) notified the Company of her resignation, effective as of June 30, 2024.
The Board of the Company following a recommendation from the independent directors of the Board, unanimously approved that Dr. Dani S. Zander be elected to fill the Class III director vacancy on the Board of the Company, effective July 1, 2024
unanimously approved that Dr. Femida H. Gwadry-Sridhar be elected to fill the Class I director vacancy on the Board of the Company, effective January 16, 2023
On December 31, 2022, Thomas C. King, a member of the Board of Directors (the “Board”) of Medpace Holdings, Inc. (the “Company”) notified the Company of his resignation from the Board, effective as of December 31, 2022.
appointments of Jesse J. Geiger to the position of President
Kevin M. Brady to the position of Chief Financial Officer
Max materiality 0.80 · Median 0.50 · Most common event earnings